TALTZ (ixekizumab), anti-interleukin 17A immunosuppressant

RHEUMATOLOGY - New indication
Opinions on drugs - Posted on Jan 25 2019

Reason for request

Extension of indication

Moderate clinical benefit for psoriatic arthritis but no proven clinical added value in the therapeutic strategy

  • TALTZ has been granted a marketing authorisation, alone or in combination with methotrexate (MTX), for the treatment of active psoriatic arthritis in adults with an inadequate response or intolerance to one or more DMARD (Disease Modifying Anti Rheumatic Drug).

  • Its efficacy has been demonstrated versus placebo on a composite criterion (ACR 20) in TNF inhibitor (TNFi) naive patients in one study, and in patients having previously received one or more TNFi in another study.

  • The effect on structural damage progression has only been assessed and demonstrated in TNFi naive patients.

  • As with ustekinumab (anti-IL 12 and 23, STELARA) and secukinumab (anti-IL 17 A, COSENTYX), it is not possible to specify the place of ixekizumab (anti-IL 17 A, TALTZ) compared to TNFi in the first-line treatment of psoriatic arthritis (i.e. in the event of failure of conventional DMARD) due to the absence of  comparative data.

Clinical Benefit



Clinical Added Value

no clinical added value